Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients.
- Author:
Hoon Suk PARK
1
;
Yuah HONG
;
In O SUN
;
Byung Ha CHUNG
;
Hyung Wook KIM
;
Bum Soon CHOI
;
Cheol Whee PARK
;
Dong Chan JIN
;
Yong Soo KIM
;
Chul Woo YANG
Author Information
1. Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. yangch@catholic.ac.kr
- Publication Type:Original Article ; Comparative Study
- Keywords:
Rituximab;
Plasmapheresis;
Glomerulosclerosis, focal segmental;
Recurrence;
Kidney transplantation
- MeSH:
Adult;
Antibodies, Monoclonal, Murine-Derived/*administration & dosage;
Female;
Glomerulosclerosis, Focal Segmental/diagnosis/immunology/*surgery;
Humans;
Immunosuppressive Agents/*administration & dosage;
*Kidney Transplantation/adverse effects;
Male;
Middle Aged;
*Plasmapheresis;
Recurrence;
Retrospective Studies;
Risk Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2014;29(4):482-488
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Recurrent focal segmental glomerulosclerosis (FSGS) following renal transplantation is relatively common. However, the risk factors and optimal pretransplant treatment preventing recurrence of FSGS remain controversial. METHODS: We retrospectively reviewed 27 adult renal transplant recipients with FSGS over a period of 10 years. We first compared possible risk factors for FSGS recurrence between the recurrence and nonrecurrence groups. Then we evaluated the effect of pretransplant plasmapheresis (PP; n = 4) and PP with rituximab (PP + RTX; n = 5) on recurrence of FSGS after transplantation compared to control patients that were not treated with these modalities. RESULTS: There were seven recurrences in 27 patients (25.9%), but there were no significant differences in possible risk factors for FSGS recurrence between the two groups. Recurrence rates between patients with pretransplant PP or PP + RTX and control patients were not significantly different (22.2% vs. 27.7%, p > 0.05). There was also no significant difference in recurrence between the pretransplant PP and PP + RTX groups (25% vs. 20%, p > 0.05). CONCLUSIONS: Pretransplant PP or PP + RTX do not significantly decrease the recurrence of FSGS in adult renal transplant candidates.
